Literature DB >> 16934247

Neuronal conditions of spinal cord in dermatitis are improved by olopatadine.

Rie Hamada1, Masahiro Seike, Reiko Kamijima, Mitsunori Ikeda, Hajime Kodama, Hiroshi Ohtsu.   

Abstract

Intense pruritus and cutaneous reactivity represent cardinal features of eczema. The resulting scratching behaviors alter neuronal conditions of the spinal dorsal horn where the primary sensory afferent fibers transmit cutaneous stimulation and deteriorate eczematous skin lesions. We investigated the effects of olopatadine hydrochloride (olopatadine) on alteration of neuronal conditions of the spinal dorsal horn and eczematous skin lesions induced by contact dermatitis. Eczematous lesions were induced by repeated application of diphenylcyclopropenone (DCP) in BALB/c mice. Olopatadine suppressed scratching behavior caused by repeated application of DCP in mice. Increased expressions of c-Fos and substance P in the spinal dorsal horn following DCP application were improved by olopatadine. Furthermore, olopatadine diminished the number of infiltrating cells and levels of cytokines in eczematous skin lesions resulting from DCP application. Olopatadine improves neurological conditions in the spinal cord and eczematous skin lesions in a murine contact dermatitis model.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16934247     DOI: 10.1016/j.ejphar.2006.06.058

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  2 in total

1.  Nalfurafine prevents 5'-guanidinonaltrindole- and compound 48/80-induced spinal c-fos expression and attenuates 5'-guanidinonaltrindole-elicited scratching behavior in mice.

Authors:  S Inan; N J Dun; A Cowan
Journal:  Neuroscience       Date:  2009-06-10       Impact factor: 3.590

2.  Spinal neurons that contain gastrin-releasing peptide seldom express Fos or phosphorylate extracellular signal-regulated kinases in response to intradermal chloroquine.

Authors:  Andrew M Bell; Maria Gutierrez-Mecinas; Erika Polgár; Andrew J Todd
Journal:  Mol Pain       Date:  2016-06-07       Impact factor: 3.395

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.